Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France
| Autor: | Chouaid, Christos, Bensimon, Lionel, Clay, Emilie, Millier, Aurélie, Levy-Bachelot, Laurie, Huang, Min, Levy, Pierre |
|---|---|
| Zdroj: | In Lung Cancer January 2019 127:44-52 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect